Chengdu Baishixing Science and Technology Industry Co., Ltd.

In 2003, in the early days, challenges abounded, but with unity we overcame them.

In 2008, it was a memorable yet tough year, devoted to both growth and earthquake relief.

In 2011, in just 100 days, a new plant rose; the massive relocation from the old site to the new one was completed within a week, opening a new chapter for Baishixing.

In 2013, facing growth limits, we stepped abroad. Within years, Baishixing gained global recognition, with its products sold in more than 20 countries.

In 2015, Dr. Shi Changqing joined and founded an innovation studio, leading key projects and securing patents that brought new vitality to the company. Today, several Baishixing products remain exclusively made in China.

In 2021, amid COVID-19, Baishixing reshaped its strategy, with annual output surpassing 100 million RMB for the first time.

In 2024, the company continued to ensure strong capacity to meet market demand and secure a first-mover advantage.

      Chengdu Baishexing Technology Industrial Co., Ltd. has established a full-chain, one-stop professional service system, capable of providing pre-sales technical consultation, product selection recommendations, formulation optimization verification, as well as core services such as customized synthesis of fine chemicals, original research and development ODM design, compliant contract manufacturing OEM large-scale production, etc. The business covers mainstream categories such as amino acid derivatives, cell culture medium raw materials, pharmaceutical intermediates, and biological active substances. It supports the full process implementation from milligram-level laboratory small-scale trials, medium-scale process scaling up to ton-scale industrial production. It can provide sample prototyping, process iteration, and compliant documentation support services as needed. Each batch of products can issue standard COA quality inspection reports. The entire process strictly signs confidentiality agreements to protect the client's intellectual property and technical secrets. At the same time, it is equipped with a professional after-sales team to provide long-term technical inquiries, quality traceability, and logistics support guarantees. Relying on the production capacity advantages of the two production bases, it continuously provides stable supply, high compatibility, and high-standard integrated cooperation solutions for domestic and foreign customers in the fields of biomedicine, biotechnology, and feed additives.

    Chengdu Baishixing Technology Industry Co., Ltd. has a high-quality and professional multi-disciplinary team. The strategic development is coordinated by Chairman and General Manager Wang Zhaowei, and compliance supervision is handled by Supervisor Zhou Yonghong. The core technology research and development is led by Dr. Shi Changqing, who joined the company in 2015 and established an innovation studio. Led a professional R&D team of about 30 people to cumulatively develop multiple key projects and overcome numerous technical difficulties. The team consists of professional talents from multiple fields such as management, R&D, production, quality inspection, and sales. Among them, the proportion of R&D personnel exceeds 15%, and it has high-qualified talents with doctoral and master's degrees as well as many senior experts in the industry. At the same time, it has established a cooperation mechanism of industry-university-research with universities such as the School of Life Sciences of Wuhan University, forming an integrated collaboration system of "R&D + production + market". The team adheres to the concept of innovation-driven development and has accumulated 16 invention patents, 16 utility model patents and 10 software Copyrights. Among them, the bromine-free production processes of L-tyrosine disodium and whoral acid have filled domestic gaps, and many technologies have achieved import substitution. It has also been deeply involved in the formulation of industry standards. It provides core support for technological innovation and market expansion in the company's four major business tracks (protective amino acids and oligopeptides, cell culture medium raw materials, bioactive substances, and pharmaceutical intermediates), helping the enterprise become a leader in the field of biopharmaceutical raw materials.